- Home
- EWTX vs APGE Comparison
EWTX vs APGE Comparison
Compare EWTX & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- APGE
- Stock Information
- Founded
- EWTX 2017
- APGE 2022
- Country
- EWTX United States
- APGE United States
- Employees
- EWTX N/A
- APGE N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EWTX Health Care
- APGE Health Care
- Exchange
- EWTX Nasdaq
- APGE Nasdaq
- Market Cap
- EWTX 3.3B
- APGE 3.0B
- IPO Year
- EWTX 2021
- APGE 2023
- Fundamental
- Price
- EWTX $31.98
- APGE $42.86
- Analyst Decision
- EWTX Strong Buy
- APGE Strong Buy
- Analyst Count
- EWTX 5
- APGE 5
- Target Price
- EWTX $40.40
- APGE $75.20
- AVG Volume (30 Days)
- EWTX 679.5K
- APGE 390.3K
- Earning Date
- EWTX 11-07-2024
- APGE 11-12-2024
- Dividend Yield
- EWTX N/A
- APGE N/A
- EPS Growth
- EWTX N/A
- APGE N/A
- EPS
- EWTX N/A
- APGE N/A
- Revenue
- EWTX N/A
- APGE N/A
- Revenue This Year
- EWTX N/A
- APGE N/A
- Revenue Next Year
- EWTX N/A
- APGE N/A
- P/E Ratio
- EWTX N/A
- APGE N/A
- Revenue Growth
- EWTX N/A
- APGE N/A
- 52 Week Low
- EWTX $5.93
- APGE $16.39
- 52 Week High
- EWTX $38.12
- APGE $72.29
- Technical
- Relative Strength Index (RSI)
- EWTX 46.84
- APGE 30.75
- Support Level
- EWTX $29.82
- APGE $57.85
- Resistance Level
- EWTX $38.12
- APGE $46.70
- Average True Range (ATR)
- EWTX 1.93
- APGE 3.86
- MACD
- EWTX -0.70
- APGE -1.57
- Stochastic Oscillator
- EWTX 26.02
- APGE 0.05
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.